menu
    • menu

    Company profile for Ventyx Biosciences

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are a biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high value targets. Ventyx now includes combined assets from three separate companies: Oppilan Pharma, targeting S1P1R, Zomagen Biosciences, targeting NLRP3 and the inflammasome, and Ventyx Biosciences, targeting TYK2.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ventyx BiosciencesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    662 Encinitas Boulevard, Suite 250 Encinitas, CA 92024
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://ventyxbio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ventyx Provides Clinical And Corporate Updates
    Ventyx Provides Clinical And Corporate Updates

    02 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/02/3197764/0/en/Ventyx-Provides-Clinical-and-Corporate-Updates.html

    GLOBENEWSWIRE
    02 Dec 2025
    Share Share
    Ventyx Biosciences Joins Piper Sandler Healthcare Conference
    Ventyx Biosciences Joins Piper Sandler Healthcare Conference

    01 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/01/3196872/0/en/Ventyx-Biosciences-to-Participate-in-the-Piper-Sandler-37th-Annual-Healthcare-Conference.html

    GLOBENEWSWIRE
    01 Dec 2025
    Share Share
    Ventyx Biosciences Joins Jefferies Global Healthcare Conference
    Ventyx Biosciences Joins Jefferies Global Healthcare Conference

    17 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/17/3188997/0/en/Ventyx-Biosciences-to-Participate-in-the-Jefferies-Global-Healthcare-Conference-in-London.html

    GLOBENEWSWIRE
    17 Nov 2025
    Share Share
    Ventyx Bio Unveils Q3 2025 Financials & Corporate Progress
    Ventyx Bio Unveils Q3 2025 Financials & Corporate Progress

    06 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/06/3183065/0/en/Ventyx-Biosciences-Reports-Third-Quarter-2025-Financial-Results-and-Highlights-Recent-Corporate-Progress.html

    GLOBENEWSWIRE
    06 Nov 2025
    Share Share
    Ventyx's CV Drug Rapidly Reduces Cardio Risk Biomarker
    Ventyx's CV Drug Rapidly Reduces Cardio Risk Biomarker

    23 Oct 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/ventyxs-cv-drug-reduces-stroke-biomarker-80-1st-week-phase-2-study

    FIERCE BIOTECH
    23 Oct 2025
    Share Share
    Ventyx Biosciences Reports Positive Phase 2 Results For VTX3232
    Ventyx Biosciences Reports Positive Phase 2 Results For VTX3232

    22 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/22/3171455/0/en/Ventyx-Biosciences-Announces-Positive-Topline-Results-from-Phase-2-Study-of-VTX3232-in-Participants-with-Obesity-and-Cardiovascular-Risk-Factors.html

    GLOBENEWSWIRE
    22 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search